A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery

• Status: Completed
• Trial end date: 2021-07-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the clinical study is to assess safety, tolerability and pharmacokinetics of RMC-035 for the prevention and treatment of acute kidney injury (AKI) in patients undergoing cardiac surgery.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guard Therapeutics AB
• Treatments: Pharmaceutical Solutions

Criteria

Key Inclusion Criteria:

• Female and male subjects with an age ≥18 years

• Subject is scheduled for non-emergent (elective) CABG and/or valve surgery (single or multiple valves) with use of cardiopulmonary bypass (CPB)

• Subject has at least ONE of the following risk factors for AKI at screening:

• History of LVEF <35% for at least 3 months prior to screening assessed by either echocardiography, cardiac MRI or nuclear scan.

• History of previous open chest cavity cardiac surgery with or without CPB

• Confirmed diagnosis of type 2 diabetes (T2DM) at least 3 months prior to screening AND ongoing treatment with an approved anti-diabetic drug

• Age ≥70 years

• Documented history of heart failure NYHA class II or higher for at least 3 months or longer at screening

• Documented history of previous AKI before date of screening independent of the etiology of AKI

• Documented history of anemia with hemoglobin ≤ 11 g/dL (≤6.8 mmol/L) for at least 3 months prior to screening

• Documented history of albuminuria, defined as UACR >30 mg/g or > 30 mg/24 hour in a 24-hour urine collection.

• eGFR is ≤ 60 mL/min/1.73 m2 using the Chronic Kidney Disease - Epidemiology Collaboration (CKD-EPI) equation

Key Exclusion Criteria:

• Estimated glomerular filtration rate (eGFR) is <30 mL/min/1.73 m2 using the Chronic Kidney Disease - Epidemiology Collaboration (CKD-EPI) equation at screening or at baseline

• Subject has surgery scheduled to be performed without CPB ("off-pump")

• Subject has surgery scheduled for aortic dissection

• Subject is scheduled for CABG and/or valve surgery combined with additional non-emergent cardiac surgeries, e.g. for atrial fibrillation ablation

• Subject is scheduled to undergo trans catheter aortic valve implantation (TAVI) or trans catheter aortic valve replacement (TAVR), or single vessel off-pump surgeries or left ventricular device (LVAD) implantation

• Subject has a requirement for any of the following within one week prior to surgery:

defibrillator or permanent pacemaker, mechanical ventilation, IABP, LVAD, other forms of mechanical circulatory support (MCS) (Note: The prophylactic insertion of an IABP preoperatively for reasons not related to existing LV pump function is not exclusionary)